SCHEMBL7675436

SCHEMBL7675436

CN(C)Cc1cccn1Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
TSHR P16473 1/20 0.50
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
KDM4E B2RXH2 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TP53 P04637 1/20 0.44
HTR6 P50406 2/20 0.43
BRD4 O60885 2/20 0.41
PDGFRB P09619 1/20 0.41
KDR P35968 1/20 0.41
BRD2 P25440 1/20 0.41
BRD3 Q15059 1/20 0.41
BRDT Q58F21 1/20 0.41
TAAR1 Q96RJ0 1/20 0.40
MAPT P10636 1/20 0.40
ADRA1D P25100 1/20 0.40
NOTUM Q6P988 1/20 0.39
DBH P09172 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodomethane SCHEMBL7678454 0.97 ALDH1A1 (0.47) ALDH1A1TSHRHDAC8HDAC6KDM4E
SCHEMBL3195611 0.79 HDAC8 (0.49) ALDH1A1HDAC8HDAC6KDM4EL3MBTL1
SCHEMBL27700003 0.77 ALDH1A1 (0.50) ALDH1A1HDAC8HDAC6KDM4EL3MBTL1
SCHEMBL386002 0.77 ALDH1A1 (0.37) ALDH1A1TSHRTAAR1
SCHEMBL27944822 0.77 ALDH1A1 (0.50) ALDH1A1HDAC8HDAC6KDM4EL3MBTL1
SCHEMBL1244069 0.76 HDAC8 (0.53) ALDH1A1TSHRHDAC8HDAC6KDM4E
SCHEMBL28191937 0.76 HDAC8 (0.49) ALDH1A1HDAC8HDAC6KDM4EL3MBTL1
SCHEMBL8217059 0.76 HDAC8 (0.49) ALDH1A1HDAC8HDAC6KDM4EL3MBTL1
SCHEMBL27502740 0.74 ALDH1A1 (0.42) ALDH1A1TSHRHDAC8HDAC6KDM4E
SCHEMBL28210000 0.74 HDAC1 (0.46) ALDH1A1TSHRHDAC8HDAC6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011011330-A2 INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2011-01-27 WO disclosed
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed
US-4070368-A ACYLATION, DECARBOXYLATION MCNEIL LABORATORIES, INCORPORATED (US) 1978-01-24 US disclosed
US-3952012-A MULTISTAGE MCNEIL LABORATORIES, INCORPORATED (US) 1976-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A ALDH1A1 208/4885TSHR 2892/4885HDAC8 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.